Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Intellia Therapeutics, Inc.NASDAQ: NTLA
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses dips below year-ago levels
Q1 FY2026 other income / expenses of $4.3M fell 33.6% year over year, behind the +72.4% change in trailing-twelve-month other income / expenses. Sequentially, it rose 47.1% from the prior quarter.
Context
- Other income / expenses amounted to 41.8% of revenue in FY2025, up 15.5 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -33.6% toward the trailing-twelve-month pace of +72.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 28.3M USD
- Year-over-year change
- +85.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.3M | +85.6% |
| FY2024 | 2024-12-31 | 15.24M | -55.3% |
| FY2023 | 2023-12-31 | 34.1M | +312.8% |
| FY2022 | 2022-12-31 | (16.02M) | -38047.6% |
| FY2021 | 2021-12-31 | (42K) | — |
Other Income / Expenses vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 other income / expenses of $26.12M is the 3rd highest of the 10 companies compared; the peer median is -$2.06M.
- Its year-over-year change of +72.4% is the 4th highest of 10, against a peer median of -46.8%.
- Other income / expenses amounts to 39.5% of revenue for NTLA, versus a peer median of 65.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $292.6M | +517.4% | +79.2% | 187.5% | |
| LTM Sep 2026 | $76.21M | +1284.2% | — | 302.7% | |
| LTM Mar 2026 | $26.12M | +72.4% | — | 39.5% | |
| LTM Mar 2026 | $6.49M | -46.8% | +29.6% | — | |
| LTM Mar 2026 | $6.16M | -32.3% | — | 15.9% | |
| LTM Mar 2026 | -$2.06M | -113.1% | — | 18.4% | |
| LTM Mar 2026 | -$4.43M | -212.0% | — | — | |
| LTM Mar 2026 | -$11.92M | +74.0% | — | 65.9% | |
| LTM Mar 2026 | -$15.34M | -85.0% | — | 19.2% | |
| LTM Jun 2026 | -$118.21M | -478.5% | — | 137.9% | |
| Peer median (excluding NTLA) | -$2.06M | -46.8% | +54.4% | 65.9% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
| Cost of Revenue | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| Gross Profit | 26.16M | 44.55M | 27.3M | 47.59M | 51.75M |
| Gross Margin | 79.2% | 85.5% | 75.3% | 82.2% | 76.5% |
| Research & Development | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| Selling, General & Admin | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M |
| Operating Expenses | 294.01M | 502.71M | 542.59M | 581.86M | 492.74M |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| EBITDA | (261M) | (466.61M) | (472.22M) | (508.74M) | (396.77M) |
| EBITDA Margin | -789.6% | -895.3% | -1301.8% | -879.0% | -586.3% |
| Operating Income | (267.85M) | (458.16M) | (515.29M) | (534.26M) | (440.99M) |
| Operating Margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Interest Income | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42K) | (16.02M) | 34.1M | 15.24M | 28.3M |
| Income Before Tax | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Pre-Tax Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Net Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (Basic) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| EPS (Diluted) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| Weighted Avg Shares | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
| Weighted Avg Shares (Diluted) | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.